https://orcid.org/0000-0002-6847-1736
Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Sophie Marbaix, Annick Mignon, Audrey Taelman, Ahuva Averin, Mark Atwood & Jeffrey Vietri. (2023) Cost-utility of 20-valent pneumococcal conjugate vaccine compared to no vaccination and recommended alternative vaccines among Belgian adults. Expert Review of Vaccines 22:1, pages 1008-1021.
Read now
Read now
Felicitas Kühne, Katharina Achtert, Franziska Püschner, Dominika Urbanski-Rini, Juliane Schiller, Ernestine Mahar, Josephine Friedrich, Mark Atwood, Ralf Sprenger, Jeffrey Vietri, Christof von Eiff & Christian Theilacker. (2023) Cost-effectiveness of use of 20-valent pneumococcal conjugate vaccine among adults in Germany. Expert Review of Vaccines 22:1, pages 921-932.
Read now
Read now
Articles from other publishers (6)
Pieter T. de Boer, Cornelis H. van Werkhoven, Albert Jan van Hoek, Mirjam J. Knol, Elisabeth A. M. Sanders, Jacco Wallinga, Hester E. de Melker & Anneke Steens. (2024) Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands. BMC Medicine 22:1.
Crossref
Crossref
Dong-Won Kang, Chae-Rin Kim, Joon Young Song & Sun-Kyeong Park. (2024) Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea. Vaccine 42:4, pages 871-878.
Crossref
Crossref
Susanne Simon, Oana Joean, Tobias Welte & Jessica Rademacher. (2023) The role of vaccination in COPD: influenza, SARS-CoV-2, pneumococcus, pertussis, RSV and varicella zoster virus. European Respiratory Review 32:169, pages 230034.
Crossref
Crossref
George Gourzoulidis, Myrto Barmpouni, Vasiliki Kossyvaki, Jeffrey Vietri & Charalampos Tzanetakos. (2023) Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece. Frontiers in Public Health 11.
Crossref
Crossref
Mikkelsen Malene B, Husby Oyvind, Molden Tor, Mwaura David N, Olsen Jens, Kristensen Nanna V & Vietri Jeffrey. (2023) Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting. Cost Effectiveness and Resource Allocation 21:1.
Crossref
Crossref
David Cantarero, Daniel Ocaña, María Ángeles Onieva-García, Juan Rodríguez-García, Paulina Gálvez, Cristina Méndez, Carlos Crespo & Alejandra López-Ibáñez de Aldecoa. (2023) Cost-utility analysis of the use of the 20-valent anti-pneumococcal vaccine (PCV20) in adults older than 60 years in Spain. Vaccine 41:36, pages 5342-5349.
Crossref
Crossref